⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901 | 1.00 | — | — | |
| SCHEMBL10491054 | 0.93 | — | — | |
| SCHEMBL9125481 | 0.93 | — | — | |
| SCHEMBL25229103 | 0.78 | — | — | |
| SCHEMBL5327872 | 0.74 | — | — | |
| SCHEMBL16861379 | 0.67 | — | — | |
| SCHEMBL4835 | 0.61 | — | — | |
| SCHEMBL846631 | 0.58 | — | — | |
| SCHEMBL18042130 | 0.58 | — | — | |
| SCHEMBL18681 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2465856-A2 | Cytochrome P450 oxidase inhibitors and uses thereof | Abbott Laboratories (US) | 2012-06-20 | — | — | EP | disclosed |
| EP-2465855-A1 | Cytochrome P450 oxidase inhibitors and uses thereof | Abbott Laboratories (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20120083490-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-04-05 | — | — | US | disclosed |
| US-8093354-B2 | Process for preparing glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110060122-A1 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-7728104-B2 | Process for preparing glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2081917-A2 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | Abbott Laboratories (US) | 2009-07-29 | — | — | EP | disclosed |
| US-6979723-B2 | Process for preparing glycopeptide phosphonate derivatives | THERAVANCE, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| EP-1419174-A4 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | THERAVANCE INC (US) | 2005-10-12 | — | — | EP | disclosed |
| US-20050020488-A1 | Process for preparing glycopeptide phosphonate derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1418933-A4 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE INC (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1418933-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | Theravance, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| EP-1419174-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | Theravance, Inc. (US) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003029270-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20030069391-A1 | Process for preparing glycopeptide phosphonate derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-04-10 | — | — | US | disclosed |
| US-20030045457-A1 | Process for preparing glycopeptide derivatives | CUMBERLAND PHARMACEUTICALS INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2003018607-A2 | PROCESS FOR PREPARING GLYCOPEPTIDE DERIVATIVES | THERAVANCE, INC. (US) | 2003-03-06 | — | — | WO | disclosed |